Massive Bio and Asklepieia will utilize their technologies to provide oncologists and patients access to clinical trials, personalized cancer treatments, and reports on adequate therapies. Plans are underway for future collaborations with BeStrong and Open Health Alliance.
Cagatay M. Culcuoglu, COO, CTO, and co-founder of Massive Bio, expressed his optimism about these alliances. "Our collaboration with Asklepieia combines precision medicine with AI-driven clinical trial matching, speeding up the introduction of clinical trials in Greece," he said.
George Kakoulidis, CEO of Asklepieia, also emphasized the transformative potential of collaborations. "Our mission, through integrating with Massive Bio's platform, is to improve patients' quality of life and contribute to the global fight against cancer. We want to expand our partnership with Massive Bio to introduce new clinical trials and leverage technology to shorten the enrollment process leveraging Massive Bio’s global expertise," he stated.
Asklepieia will leverage its platform to identify patients who could most benefit from novel clinical trials, expanding Massive Bio's trials' reach. Concurrently, BeStrong and Open Health Alliance will provide physicians with updated clinical trial information for faster patient referrals, real-time support, and access to cancer patients or caregivers in Greece.
Massive Bio will use its AI to process patient clinical health data. Caglar Demirbag, director of international partnerships at Massive Bio, stated, "Our partnerships will improve access to cancer treatments in the region and promote diversity in clinical trial participation."
Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial. (2023, August 2). Business Wire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.